AIMD
Price
$0.54
Change
-$0.00 (-0.00%)
Updated
Apr 3 closing price
Capitalization
6.73M
MBOT
Price
$1.57
Change
-$0.13 (-7.65%)
Updated
Apr 3 closing price
Capitalization
18.57M
39 days until earnings call
Ad is loading...

AIMD vs MBOT

Header iconAIMD vs MBOT Comparison
Open Charts AIMD vs MBOTBanner chart's image
Ainos
Price$0.54
Change-$0.00 (-0.00%)
Volume$233.11K
Capitalization6.73M
Microbot Medical
Price$1.57
Change-$0.13 (-7.65%)
Volume$698.03K
Capitalization18.57M
AIMD vs MBOT Comparison Chart
Loading...
AIMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MBOT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AIMD vs. MBOT commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AIMD is a StrongBuy and MBOT is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (AIMD: $0.54 vs. MBOT: $1.58)
Brand notoriety: AIMD and MBOT are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: AIMD: 130% vs. MBOT: 33%
Market capitalization -- AIMD: $6.73M vs. MBOT: $18.57M
AIMD [@Medical Specialties] is valued at $6.73M. MBOT’s [@Medical Specialties] market capitalization is $18.57M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AIMD’s FA Score shows that 0 FA rating(s) are green whileMBOT’s FA Score has 0 green FA rating(s).

  • AIMD’s FA Score: 0 green, 5 red.
  • MBOT’s FA Score: 0 green, 5 red.
According to our system of comparison, both AIMD and MBOT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AIMD’s TA Score shows that 5 TA indicator(s) are bullish while MBOT’s TA Score has 4 bullish TA indicator(s).

  • AIMD’s TA Score: 5 bullish, 4 bearish.
  • MBOT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, AIMD is a better buy in the short-term than MBOT.

Price Growth

AIMD (@Medical Specialties) experienced а +4.79% price change this week, while MBOT (@Medical Specialties) price change was +2.94% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -4.68%. For the same industry, the average monthly price growth was +1.30%, and the average quarterly price growth was +1.15%.

Reported Earning Dates

AIMD is expected to report earnings on Feb 28, 2024.

MBOT is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Medical Specialties (-4.68% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MBOT($18.6M) has a higher market cap than AIMD($6.73M). MBOT YTD gains are higher at: 40.179 vs. AIMD (19.496). AIMD has higher annual earnings (EBITDA): -8.75M vs. MBOT (-10.75M). MBOT has more cash in the bank: 8.15M vs. AIMD (1.89M). MBOT has less debt than AIMD: MBOT (245K) vs AIMD (5.96M). AIMD has higher revenues than MBOT: AIMD (122K) vs MBOT (0).
AIMDMBOTAIMD / MBOT
Capitalization6.73M18.6M36%
EBITDA-8.75M-10.75M81%
Gain YTD19.49640.17949%
P/E RatioN/AN/A-
Revenue122K0-
Total Cash1.89M8.15M23%
Total Debt5.96M245K2,434%
FUNDAMENTALS RATINGS
AIMD vs MBOT: Fundamental Ratings
AIMD
MBOT
OUTLOOK RATING
1..100
2815
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
55
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
5236
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AIMD's Valuation (49) in the null industry is in the same range as MBOT (55) in the Biotechnology industry. This means that AIMD’s stock grew similarly to MBOT’s over the last 12 months.

AIMD's Profit vs Risk Rating (100) in the null industry is in the same range as MBOT (100) in the Biotechnology industry. This means that AIMD’s stock grew similarly to MBOT’s over the last 12 months.

AIMD's SMR Rating (98) in the null industry is in the same range as MBOT (99) in the Biotechnology industry. This means that AIMD’s stock grew similarly to MBOT’s over the last 12 months.

MBOT's Price Growth Rating (36) in the Biotechnology industry is in the same range as AIMD (52) in the null industry. This means that MBOT’s stock grew similarly to AIMD’s over the last 12 months.

MBOT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as AIMD (100) in the null industry. This means that MBOT’s stock grew similarly to AIMD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AIMDMBOT
RSI
ODDS (%)
Bullish Trend 1 day ago
72%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
85%
MACD
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
72%
Advances
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 18 days ago
72%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 10 days ago
84%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
View a ticker or compare two or three
Ad is loading...
AIMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MBOT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NEXA6.200.01
+0.16%
Nexa Resources SA
PAVM0.66-0.02
-2.31%
PAVmed
TSBK28.78-1.89
-6.16%
Timberland Bancorp
STT82.83-6.76
-7.55%
State Street Corp
ZGN6.47-0.91
-12.33%
Ermenegildo Zegna NV

AIMD and

Correlation & Price change

A.I.dvisor tells us that AIMD and CRMD have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AIMD and CRMD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AIMD
1D Price
Change %
AIMD100%
+1.85%
CRMD - AIMD
28%
Poorly correlated
-3.17%
XLO - AIMD
26%
Poorly correlated
-4.24%
DHAI - AIMD
26%
Poorly correlated
-18.26%
POAI - AIMD
26%
Poorly correlated
-2.14%
MBOT - AIMD
25%
Poorly correlated
-7.65%
More

MBOT and

Correlation & Price change

A.I.dvisor indicates that over the last year, MBOT has been loosely correlated with CORBF. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if MBOT jumps, then CORBF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MBOT
1D Price
Change %
MBOT100%
-7.65%
CORBF - MBOT
33%
Loosely correlated
N/A
OTCFF - MBOT
32%
Poorly correlated
N/A
POAI - MBOT
31%
Poorly correlated
-2.14%
RCEL - MBOT
31%
Poorly correlated
-3.84%
BNGO - MBOT
28%
Poorly correlated
-10.40%
More